Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fibroids

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Fibroids. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-004221-41 Sponsor Protocol Number: BAY1002670/17541 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046784 Uterine fibroids LLT
    17.1 100000004864 10016628 Fibroids LLT
    17.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) NL (Completed) GB (Completed) FI (Completed) AT (Completed) CZ (Completed) HU (Completed) LT (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003945-40 Sponsor Protocol Number: BAY1002670/15788 Start Date*: 2014-05-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of different doses of BAY 1002670 in subjects with uterine fibroids over 3 months
    Medical condition: Women, 18 to 50 years old, with uterine fibroids documented by transvaginal or abdominal ultrasound at screening with at least 1 uterine fibroid with largest diameter >=3.0 cm and heavy menstrual b...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10046784 Uterine fibroids LLT
    16.1 100000004864 10016628 Fibroids LLT
    16.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) FI (Completed) NO (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001461-40 Sponsor Protocol Number: 01 Start Date*: 2011-10-28
    Sponsor Name:Hull and East Yorkshire Acute Hospitals NHS Trust
    Full Title: A comparison of Mirena use in women with and without fibroids
    Medical condition: Menorrhagia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002855-48 Sponsor Protocol Number: BAY1002670/15789 Start Date*: 2017-07-12
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046784 Uterine fibroids LLT
    20.0 100000004864 10016628 Fibroids LLT
    20.0 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) SE (Completed) CZ (Completed) HU (Prematurely Ended) FI (Completed) AT (Prematurely Ended) NO (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) SK (Completed) LT (Completed) NL (Prematurely Ended) PT (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005022-38 Sponsor Protocol Number: T366/2017 Start Date*: 2018-06-13
    Sponsor Name:Turku University Hospital
    Full Title: Oxytocin in mr guided focused ultrasound treatment (MRI-HIFU)
    Medical condition: women with uterine fibroids or adenomyosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10016628 Fibroids LLT
    20.0 10038604 - Reproductive system and breast disorders 10056268 Adenomyosis PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004822-41 Sponsor Protocol Number: BAY1002670/16953 Start Date*: 2017-07-13
    Sponsor Name:Bayer AG
    Full Title: An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of vilaprisan in subjects with uterine fibroids versus standard of care
    Medical condition: Women, 18 years or older, diagnosis of uterine fibroid(s) documented by ultrasound at screening and/or during a uterine preserving procedure within 3 months prior to screening in subjects with high...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10016628 Fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002832-15 Sponsor Protocol Number: 49916 Start Date*: 2014-12-17
    Sponsor Name:VU university medical center
    Full Title: Ulipristal versus Gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy: a double blind randomized controlled trial
    Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard which removes the fibroids entirely, preferably lapa...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005120-16 Sponsor Protocol Number: 62638 Start Date*: 2018-11-02
    Sponsor Name:Amsterdam UMC, Location VUmc
    Full Title: Ulipristal versus standard surgical treatment in symptomatic uterine fibroids
    Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard, preferably laparoscpically, because it removes the ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004059-53 Sponsor Protocol Number: 16-OBE2109-009 Start Date*: 2017-05-25
    Sponsor Name:ObsEva SA
    Full Title: A Phase 3, multicentre, randomized, double-blind, placebo controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back thera...
    Medical condition: Treatment of heavy menstrual bleeding associated with uterine fibroids.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021126 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000082-37 Sponsor Protocol Number: M12-813 Start Date*: 2013-12-23
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
    Medical condition: Heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000964-16 Sponsor Protocol Number: 1311-BCN-138-DG Start Date*: 2015-03-30
    Sponsor Name:IVI Valencia
    Full Title: Uterine fibroids: Impact of ulipristal acetate 10 mg on ART results.
    Medical condition: Uterine Fibroids and Assisted Reproduction
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004425-41 Sponsor Protocol Number: ESN364-UF-02 Start Date*: 2015-01-21
    Sponsor Name:Euroscreen S.A
    Full Title: A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With ...
    Medical condition: Uterine Fibroids
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005641-19 Sponsor Protocol Number: ENG K001 GF / EC 406 Start Date*: Information not available in EudraCT
    Sponsor Name:Takeda Pharma GmbH
    Full Title: 3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients with Ut...
    Medical condition: Uterine fibroids (Uterus myomatosus)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10046784 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003561-26 Sponsor Protocol Number: BAY1002670/15790 Start Date*: 2017-12-14
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10016628 Fibroids LLT
    21.1 100000004864 10046784 Uterine fibroids LLT
    21.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002997-38 Sponsor Protocol Number: BAY1002670/15787 Start Date*: 2018-01-10
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10016628 Fibroids LLT
    21.1 100000004864 10046784 Uterine fibroids LLT
    21.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-005113-50 Sponsor Protocol Number: MVT-601-3002 Start Date*: 2017-05-22
    Sponsor Name:Myovant Sciences GmbH
    Full Title: LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    20.0 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000452-19 Sponsor Protocol Number: 20-OBE2109-007 Start Date*: 2021-04-29
    Sponsor Name:ObsEva S.A.
    Full Title: A long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix, PRIMROSE 1 or PRIMROSE 2
    Medical condition: Treatment of heavy menstrual bleeding associated with uterine fibroids.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019810-26 Sponsor Protocol Number: 1968 Start Date*: 2011-09-09
    Sponsor Name:King's College Hospital Foundtion NHS Trust
    Full Title: A randomised controlled trial to investigate the effects of the use of pre-operative GnRH analogue and intra-operative mechanical tourniquet for myomectomy on surgical blood loss, future fertility ...
    Medical condition: Uterine Fiboids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003727-27 Sponsor Protocol Number: MVT-601-3001 Start Date*: 2017-06-12
    Sponsor Name:Myovant Sciences GmbH c/o Vischer AG
    Full Title: LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    20.0 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003310-74 Sponsor Protocol Number: MVT-601-3003 Start Date*: 2018-03-21
    Sponsor Name:Myovant Sciences GmbH
    Full Title: LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Ace...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    21.1 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) CZ (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:13:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA